The ⌬Phe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ⌬Phe508-CFTR folding/cellular processing ("correctors") or chloride channel gating ("potentiators") have been discovered and are in clinical trials, single compounds with bona fide dual corrector and potentiator activities have not been identified. Here, screening of ϳ110,000 small molecules not tested previously revealed a cyanoquinoline class of compounds with independent corrector and potentiator activities (termed CoPo). Analysis of 180 CoPo analogs revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potentiator activity. N-(2-((3-Cyano-5,7-dimethylquinolin-2-yl)amino)ethyl)-3-methoxybenzamide (CoPo-22), which was synthesized in six steps in 52% overall yield, had low micromolar EC 50 for ⌬Phe508-CFTR corrector and potentiator activities by short-circuit current assay. Maximal corrector and potentiator activities were comparable with those conferred by the bithiazole Corr-4a and the flavone genistein, respectively. CoPo-22 also activated wild-type and G551D CFTR chloride conductance within minutes in a forskolin-dependent manner. Compounds with dual corrector and potentiator activities may be useful for singledrug treatment of cystic fibrosis caused by ⌬Phe508 mutation.
Introduction
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel expressed in airway, intestinal, pancreatic, and other epithelia. Deletion of phenylalanine at residue 508 (⌬Phe508) in CFTR, which is by far the most common CF-causing CFTR mutation, is present in at least one allele in ϳ90% of patients with CF. Whereas the wild-type CFTR protein functions as a chloride channel at the apical plasma membrane of target cells, the ⌬Phe508-CFTR protein is misfolded and largely retained at the endoplasmic reticulum (ER) for degradation by the ubiquitin proteasome system. A small fraction of newly synthesized ⌬Phe508-CFTR, however, can reach the cell surface in a tissue-specific manner but exhibits impaired channel gating and metabolic stability (Cheng et al., 1990; Dalemans et al., 1991; Lukacs et al., 1994) . Multiple structural defects have been identified in ⌬Phe508-CFTR, affecting four of its five domains to various extents, including the first nucleotide binding domain, in which the ⌬Phe508 mutation is located, the nucleotide binding domain 2, and membrane-spanning domains 1 and 2 (Du and Lukacs, 2009; Thibodeau et al., 2010) .
There is great interest in the development of drugs that restore chloride permeability to CF cells (Riordan, 2008; Verkman and Galietta, 2009 ). An ideal drug for treatment of CF caused by the ⌬Phe508 mutation would be a single, nontoxic small molecule that normalizes defective ⌬Phe508-CFTR folding and cellular processing, fully restoring cell chloride permeability. The drug discovery strategy used to date, as first introduced by our laboratory, uses separate assays for the identification of ⌬Phe508-CFTR "potentiators," which normalize defective ⌬Phe508-CFTR chloride channel gating, and "correctors," which correct defective ⌬Phe508-CFTR protein processing and promote ER-to-plasma membrane targeting. Using cell-based high-throughout screens, we reported small-molecule ⌬Phe508-CFTR potentiators (Yang et al., 2003; Pedemonte et al., 2005b ; benzothiophenes, phenylglycines, and sulfonamides) and correctors (Pedemonte et al., 2005a; Yu et al., 2008; Ye et al., 2010; aminoarylthiazoles and bithiazoles) . Subsequent small-scale screening by several groups identified additional candidate potentiators (Van Goor et al., 2006; Pedemonte et al., 2007) and correctors (Noël et al., 2008; Robert et al., 2008 Robert et al., , 2010 Kalid et al., 2010; Sampson et al., 2011) . A potentiator, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770) (Van Goor et al., 2009) , and a corrector, VX-809 (Van Goor et al., 2010) , identified by Vertex Pharmaceuticals are in clinical trials (Accurso et al., 2010) . In a recent proof-of-concept study, we synthesized a hybrid bithiazolephenylglycine corrector-potentiator which, when cleaved by intestinal enzymes, yielded an active bithiazole corrector and phenylglycine potentiator (Mills et al., 2010) . Pedemonte et al. (2011) have reported that aminoarylthiazoles, which were identified in our original corrector screen (Pedemonte et al., 2005a) , had corrector activity, as reported previously, and the ability to correct defective ⌬Phe508-CFTR gating when incubated with cells over many hours. However, a bona fide potentiator should exert its effect within minutes (see below).
The goal of this study was to identify dual-acting compounds with independent ⌬Phe508-CFTR potentiator and corrector activities. Potentiator activity is defined as compound efficacy in increasing ⌬Phe508-CFTR chloride conductance at the cell plasma membrane. Operationally, potentiator activity is assayed in low-temperature rescued ⌬Phe508-CFTR-expressing cells in which ⌬Phe508-CFTR is targeted to the plasma membrane by Ͼ12-h incubation at reduced temperature, and test compound (together with cAMP agonist) is added just before or at the time of fluorescence or electrophysiological assay (Yang et al., 2003) . Corrector activity is defined as compound efficacy in increasing ⌬Phe508-CFTR cell surface expression. Corrector activity is assayed in ⌬Phe508-CFTR-expressing cells by Ͼ12 h incubation with test compound at 37°C, followed by washout and incubation with a potentiator such as genistein (together with cAMP agonist) just before or at the time of assay (Pedemonte et al., 2005a) . We report here the identification a cyanoquinoline class of compounds having independent corrector and potentiator activities, termed CoPo. Although the corrector and potentiator activities of CoPos depended on their chemical structure and cell type, the cyanoquinolines are the first class of compounds with bona fide corrector and potentiator activities, providing rationale for their further chemical optimization and for additional screening to identify other compound classes with dual corrector and potentiator activities.
Materials and Methods

Cell Lines
Fisher rat thyroid (FRT) epithelial cells were stably transfected with ⌬Phe508, G551D, or wild-type CFTR as reported previously (Pedemonte et al., 2005b) . A549 cells stably expressing ⌬Phe508-CFTR were provided by Dr. Luis Galietta (Genoa, Italy). Each of the CFTR-expressing cell lines (and the nontransfected parental cells) was also transfected with halide-sensitive green fluorescent protein YFP-H148Q/I152L/F46L. FRT cells were cultured in Coon's modified Ham's F-12 medium and A549 cells in Dulbecco's modified Eagle's medium/Ham's F-12 (1:1). All media were supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. For primary screening, ⌬Phe508-CFTR-expressing FRT cells were plated in black, 96-well microplates (Corning Life Sciences, Lowell, MA) at 50,000 cells/well. For short-circuit current measurements, cells were cultured on Snapwell permeable supports (Corning Life Sciences) at 500,000 cells/insert.
Compounds
A total of 110,000 diverse drug-like synthetic compounds (Ͼ90% with molecular masses of 250 -500 Da; ChemDiv Inc., San Diego, CA, and Asinex Inc., Moscow, Russia) were used for initial screening. For optimization, ϳ180 commercially available cyanoquinoline analogs were tested. Structures of active compounds were confirmed by 1 H NMR and liquid chromatography/mass spectrometry.
Screening Procedures
Screening was carried out using a Beckman Coulter platform equipped with FLUOstar fluorescence plate readers (Optima; BMG Labtech, Durham, NC) with dual syringe pumps and 500 Ϯ 10 nm excitation and 535 Ϯ 15 nm emission filters (Chroma Corporation, McHenry, IL). For corrector assay, FRT cells were grown at 37°C/5% CO 2 for 18 to 24 h and then incubated for 18 to 24 h with 100 l of medium containing test compounds (25 M final concentration). At the time of the assay, cells were washed with PBS and then incubated for 10 min with PBS containing forskolin (20 M) and genistein (50 M). For potentiator assay, FRT cells were grown at 37°C/5% CO 2 for 18 to 24 h and then for 18 to 24 h at 27°C. At the time of the assay, cells were washed with PBS and then incubated for 10 min with PBS (50 l) containing forskolin (20 M) and test compound (0 -25 M final concentration). For both of the corrector and potentiator assays, each well was assayed individually for I Ϫ influx by recording fluorescence continuously (200 ms per point) for 2 s (baseline) and then for 12 s after rapid addition of 165 l of PBS, in which 137 mM Cl Ϫ was replaced by I Ϫ . Initial I Ϫ influx rate was computed by fitting the final 11.5 s of the data to an exponential for extrapolation of initial slope, which was normalized for backgroundsubtracted initial fluorescence. All compound plates contained negative controls (DMSO vehicle) and positive controls (10 M Corr-4a for corrector assay; 50 M genistein for potentiator assay).
Short-Circuit Current Measurements
⌬Phe508-CFTR-expressing FRT cells were cultured on Snapwell inserts for 7 to 9 days. For corrector testing, test compounds were incubated with FRT cells for 18 to 24 h at 37°C before measurements. For potentiator testing, the FRT cells were incubated for 18 to 24 h at 27°C before measurements. The basolateral solution contained 130 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 1 mM CaCl 2 , 0.5 mM MgCl 2 , 10 mM glucose, and 10 mM sodium-HEPES, pH 7.3. In the apical bathing solution, 65 mM NaCl was replaced by sodium gluconate, and CaCl 2 was increased to 2 mM. Solutions were bubbled with air and maintained at 37°C. The basolateral membrane was permeabilized with 250 g/ml amphotericin B. Hemichambers were connected to a DVC-1000 voltage clamp (World Precision Instruments, Inc., Sarasota, FL) via 
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Ag/AgCl electrodes and 1 M KCl agar bridges for recording of shortcircuit current.
CFTR Immunoblot
⌬Phe508-CFTR-expressing FRT cells grown on six-well plates were treated with amino)ethyl)-3-methoxybenzamide (CoPo-22; 20 M), or vehicle (DMSO) at 37°C for 24 h. After treatment, cells were washed with PBS and lysed in 20 mM HEPES, pH 7, 150 mM NaCl, 1 mM EGTA, and 1% Igepal containing complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). After preclearing, lysates were subjected to SDSpolyacrylamide gel electrophoresis and analyzed by immunoblot. Proteins were immunodetected using a mouse monoclonal anti-CFTR antibody (M3A7; Millipore Corporation, Billerica, MA) followed by horseradish peroxidase-conjugated anti-mouse IgG, and visualized by chemiluminescence (ECL Plus; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Cyclic Nucleotide Assay
FRT cells expressing ⌬Phe508-CFTR were grown in six-well plates and incubated with CoPo-22 (0, 5, and 10 M) for 10 min at 37°C in the absence or presence of forskolin (20 M) or forskolin ϩ isobutyl methylxanthine (500 M). Cells were lysed by freeze-thaw, centrifuged to remove cell debris (600g, 10 min, 4°C), and assayed for cAMP using a parameter cAMP immunoassay kit (R&D Systems, Minneapolis, MN).
CoPo-22 Synthesis
N-(3,5-Dimethylphenyl)acetamide (1). Acetic anhydride (2.84 ml, 30 mmol) was dissolved in dry tetrahydrofuran (10 ml), purged with N 2 , and brought to 0°C. 3,5-Dimethylaniline (1.25 ml, 10 mmol) was then added drop-wise. After the addition of the aniline, the reaction was allowed to warm to room temperature and stirred for an additional hour. The solution was then poured over ice and 1 M NaOH (aqueous) was added until the pH was between 12 and 14. The precipitate was filtered, dissolved in dichloromethane (DCM), and dried over Na 2 SO 4 . The drying agent was filtered and solvent was removed under reduced pressure to afford pure product in 99% yield as a white solid (Moussaoui et al., 2002) .
2-Chloro-5,7-dimethylquinoline-3-carbaldehyde (2). Phosphorous oxychloride (6.52 ml, 70 mmol) and dry dimethylformamide (1.94 ml, 25 mmol) were refluxed for 2 h under N 2 . Acetamide 1 (1.632 g, 10 mmol) was added to the reaction solution as a solid and stirred at room temperature for an additional 3 h. The solution was poured slowly over ice, diluted with water (200 ml), and neutralized with solid K 2 CO 3 . The precipitate was then filtered, dissolved in chloroform, and dried over Na 2 SO 4 . The drying agent was filtered and solvent was removed under reduced pressure to afford pure product as an orange solid in 95% yield (Moussaoui et al., 2002) .
2-Chloro-5,7-dimethylquinoline-3-carbonitrile (3). Aldehyde 2 (1.095 g, 5 mmol), hydroxylamine hydrochloride (0.365 g, 5.25 mmol), and triethylamine (1.00 ml, 7 mmol) were combined in ethanol (50 ml). The solution was refluxed for 3 h, and then the ethanol was removed under reduced pressure. HCl (1 M aqueous, 100 ml) at ASPET Journals on May 1, 2017 molpharm.aspetjournals.org was added to the crude material, and product was extracted with DCM (100 ml). The organic layer was separated and dried over Na 2 SO 4 , the drying agent was removed by filtration, and the solvent was removed under reduced pressure. The crude product was then dissolved in 50 ml of dry benzene. Thionyl chloride (0.73 ml, 10 mmol) was added drop-wise to the solution, and the reaction was refluxed for 4 h under N 2 . The solution was allowed to cool to room temperature, then the benzene and excess thionyl chloride were removed under reduced pressure to afford the known product 3 in 93% yield as a light brown solid [ 1 H NMR (400 MHz, CDCl 3 ) ␦ 8.62 (s, 1H), 7.62 (s, 1H), 7.33 (s, 1H), 2.66 (s, 3H), 2.54 (s, 3H)], which was used directly in the next reaction.
2-((2-Aminoethyl)amino)-5,7-dimethylquinoline-3-carbonitrile (4). Carbonitrile 3 (1.083 g, 5 mmol) and 1,2-aminoethane (1.00 ml, 15 mmol) were refluxed in dioxane (50 ml). The reaction was allowed to cool to room temperature, and dioxane was removed under reduced pressure. The crude product was suspended in saturated NH 4 Cl (aqueous) and filtered. The solids were washed with diethyl ether and allowed to dry on filter paper under vacuum to give the known product 4 in 80% yield [ 1 H NMR (400 MHz, CDCl 3 ) ␦ 8.31 (s, 1H), 7.32 (s, 1H), 6.92 (s, 1H), 5.64 (t, J ϭ 4.8, 1H), 3.65 (q, J ϭ 5.7, 2H), 3.01 (t, J ϭ 6.0, 2H), 2.52 (s, 3H), 2.42 (s, 3H)], which was used directly in the next reaction.
CoPo-22. EDC hydrochloride (0.192 g, 1 mmol), m-anisic acid (0.152 g, 1 mmol), and triethylamine (0.14 ml, 2.5 mmol) were dissolved in dry DCM (10 ml). The reaction was stirred at room temperature for 30 min. Carbonitrile 4 (0.201g, 1 mmol) dissolved in 5 ml of dry DCM was added drop-wise to the solution, and the reaction was stirred for 18 h. The reaction was diluted with DCM (50 ml) and washed with 1 M NaHSO 4 (aqueous, 2 ϫ 100 ml). Organics were dried over Na 2 SO 4 , filtered, and solvent was removed under reduced pressure. The crude product was then purified by flash chromatography (4:1 hexane/ethyl acetate mobile phase) to produce a light yellow solid 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, 2957 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 2925 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 2217 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 1605 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 1583 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 1535 10, 159.87, 155.10, 144.27, 140.97, 136.27, 135.41, 129.42, 127.13, 124.48, 119.35, 119.23, 117.72, 116.87, 112.46, 94.30, 55.49, 43.39, 41.25, 29.92, 22.21, 18.57. IR (neat): 3380, 3357, , 1258 
Results
Identification of Cyanoquinoline Correctors/Potentiators of ⌬Phe508-CFTR. Screening of ϳ110,000 small Table 1 for activity data of CoPo analogs). B, concentration-dependence of corrector (left) and potentiator (right) activities of CoPo-01, CoPo-02, CoPo-05, and CoPo-08. C, CoPo-22 synthesis scheme. molecules was done to identify new ⌬Phe508-CFTR corrector scaffolds having high correction efficiency or having independent potentiator activity. As diagrammed in Fig. 1A (left) , primary screening for corrector activity was done using a cell-based fluorescence assay of iodide influx in which FRT cells expressing ⌬Phe508-CFTR and an iodide-sensitive YFP were incubated with test compounds at 10 M for 18 to 24 h before assay. Iodide influx was measured by the addition of extracellular iodide in the presence of maximal concentrations of a potentiator (50 M genistein) and cAMP agonist (20 M forskolin). Compound efficacy and potency (from concentration-dependence studies) in the corrector assay were compared with reference bithiazole Corr-4a (10 M) and to low-temperature-rescued cells. Active compounds were counter-screened for potentiator activity (Fig. 1A, right) , in which iodide influx was measured in the ⌬Phe508-CFTR expressing FRT cells after low-temperature rescue (to target ⌬Phe508-CFTR to the plasma membrane) and in the presence of 20 M forskolin.
Screening yielded three novel scaffolds with corrector activity (Fig. 1B) , which was verified by CFTR inh -172 inhibition of corrector-dependent iodide influx and inability to increase iodide influx in FRT null cells (data not shown). Although none of the three compounds had greater corrector potency than Corr-4a, the cyanoquinoline CoPo-22 showed independent potentiator activity. Representative iodide influx data from the corrector (left) and potentiator (right) fluorescence plate reader assays of CoPo-22 are shown in Fig. 1C . We have not observed potentiator activity previously by a ⌬Phe508-CFTR corrector, in which compound is added only a few minutes before assay. Concentration-dependence data are shown in Fig. 1D . As shown by electrophysiological analysis below, the maximal efficacy of CoPo-22 corrector and potentiator actions were comparable with those of the bithiazole Corr-4a and the flavone genistein, respectively.
Synthesis and Structure-Activity Relationship Analysis of CoPo-22. In an attempt to identify CoPo analogs with improved potency as well as to establish initial structure-activity relationship data of the core cyanoquinoline scaffold, we screened 180 commercially available analogs of CoPo-22. Table 1 summarizes corrector and potentiator activities (EC 50 and V max from concentration-dependence studies) of active compounds, and Fig. 2A summarizes the structural requirements for corrector and potentiator activities. Figure 2B shows representative concentration-dependence data for four analogs. The majority of the 180 cyanoquinoline analogs were inactive. Six compounds showed both corrector and potentiator activities, with CoPo-22 being the most potent corrector. CoPo-01 and CoPo-02 are structurally similar to CoPo-22 and have corrector and potentiator activities comparable with those of CoPo-22. Compounds containing heterocycles, such as the thiophene CoPo-03 and the benzosulfonamide CoPo-05, also show dual activities, albeit of lower potency and/or maximum efficacy. Interestingly, several compounds, such as CoPo-14, showed potentiator-only activity. Replacing the ethylene bridge with a piperazine or 1,4-diazepane ring diminished or abolished corrector activity (comparing . No compounds were identified with corrector-only activity. These data suggest that the dual corrector-potentiator activity is not a general feature of cyanoquinolines but is dependent on the particular scaffold and substituents.
For further characterization studies, we resynthesized CoPo-22 in Ͼ98% purity in six steps with an overall yield of (Fig. 2C) . Acetylation of commercially available 3,5-dimethylaniline produced the corresponding acetamide in near quantitative yield. Formation of the quinoline ring was achieved through reaction with phosphorous oxychloride, giving 2-chloroquinoline carbaldehyde. Condensation of the carbaldehyde with hydroxylamine followed by dehydration using thionyl chloride gave the cyanoquinoline core in 93% yield. Displacement of the chloride by 1,2-di-aminoethane gave the aminocyanoquinoline, which was coupled with manisic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide to give CoPo-22 in 73% yield after purification.
Characterization of CoPo-22 Corrector Activity. To investigate whether CoPo-22 corrector activity is additive with low-temperature rescue, as found previously for Corr-4a (Pedemonte et al., 2005a) , ⌬Phe508-CFTR expressing FRT cells were incubated with CoPo-22 (20 M) or Corr-4a (10 M) for 24 h at 27 or 37°C. As shown in Fig. 3A , CoPo-22 and Corr-4a each increased iodide influx at 37°C, with the need for inclusion of genistein. Both compounds substantially increased iodide influx at 27°C in an approximately additive manner with low-temperature rescue (control, 27°C), suggesting different mechanisms for low-temperature rescue and corrector action. To further investigate the forskolin requirement to increase ⌬Phe508-CFTR conductance in the corrector assay, a forskolin concentration-dependence was done in the ⌬Phe508-CFTR-expressing FRT cells after corrector incubation and/or low-temperature rescue. Figure 3B shows that substantial increase in iodide influx by each of the rescue/corrector maneuvers required relatively high concentrations of forskolin compared with that of Ͻ1 M needed for activation of wild-type CFTR.
Short-circuit current was measured as a definitive electrophysiological assay to verify CoPo-22 corrector action. Apical membrane chloride current was measured in ⌬Phe508-CFTRexpressing FRT cells after basolateral membrane permeabilization and in the presence of a transepithelial chloride gradient (apical, 65 mM; basolateral, 130 mM). Figure 3C shows increased apical membrane current when cells were incubated for 18 to 24 h with increasing [CoPo-22] before short-circuit current assay. The increased apical membrane current was fully inhibited by CFTR inh -172. The increase in apical membrane current conferred by 5 and 10 M CoPo-22 was comparable with that conferred by 5 M Corr-4a (Fig. 3C, right) . Figure 3D summarizes CoPo-22 concentration dependence data from short-circuit current studies.
To investigate possible synergy between CoPo-22 and Corr-4a in corrector efficacy, a Corr-4a concentration-dependence was done at submaximal of 0.3 and 1 M, which did not by itself increase iodide influx significantly. Figure 4A shows a small but significant increase in iodide influx at relatively high for 1 versus 0 M CoPo-22. We further investigated additivity from measurements of iodide influx done after incubation with maximal concentrations of CoPo-22 and Corr-4a, alone or in combination. Figure  4B shows significant additivity of CoPo-22 and Corr-4a action, supporting the possibility of independent actions of these correctors.
The action of CoPo-22 as a corrector of defective ⌬Phe508-CFTR cellular processing was verified by CFTR immunoblot analysis. Wild-type CFTR was detected as a strong band at 170 kDa (band C), corresponding to complex glycosylated CFTR. Little or no band C for ⌬Phe508-CFTR was detected in the absence of corrector, but band C was visualized after 24-h incubation at 37°C with CoPo-22 or Corr-4a. Band B, which corresponds to core-glycosylated ⌬Phe508-CFTR, was also seen.
Characterization of CoPo-22 Potentiator Activity. Short-circuit current measurements were done to characterize CoPo-22 potentiator activity, in which apical membrane chloride current was measured in ⌬Phe508-CFTR-expressing FRT cells, after low-temperature rescue, in response to CoPo-22 additions. Figure 5A shows CoPo-22 concentrationdependent increases in apical membrane current seen in the presence of forskolin. The lack of CoPo-22 effect in the absence of forskolin indicates the need for ⌬Phe508-CFTR phosphorylation, as has been found for other potentiators. Genistein produced a small increase in chloride current after maximal CoPo-22. CFTR inh -172 abolished all chloride cur- To further investigate CoPo-22 potentiator action, shortcircuit current was measured in FRT cells expressing wildtype CFTR (Fig. 5B ). Studies were done as in Fig. 5A , except that low concentrations of forskolin (0-0.5 M) were used because higher concentrations fully activate wild-type CFTR and thus would mask CoPo-22 potentiator action. As found for ⌬Phe508-CFTR, there was little effect of CoPo-22 in the absence of forskolin. In each experiment, after CoPo-22 additions, 10 M forskolin was added to fully activate wild-type CFTR, followed by 50 M genistein, which had little effect, followed by 10 M CFTR inh -172, which inhibited all chloride current. CoPo-22 partially activated wild-type CFTR when added after 0.25 or 0.5 M forskolin, with EC 50 ϳ10 M.
Potentiator studies were also done in FRT cells expressing G551D-CFTR, a CF-causing CFTR mutation with defective channel gating but not plasma membrane trafficking. Figure 6A shows that CoPo-22 functioned as a weak potentiator of G551D-CFTR, producing a smaller increase in chloride current than that produced by genistein. Fluorescence plate reader assays in Fig. 6B confirmed that CoPo-22 activated G551D-CFTR in the presence of forskolin, albeit with lower maximal efficacy than genistein. Apparent EC 50 for CoPo-22 activation of G551-CFTR was ϳ5 M (Fig. 6A, bottom) , with maximum efficacy much lower than that of genistein.
CoPo-22 did not affect cellular cAMP levels in assays done on the FRT cells after 10-min incubation with CoPo-22 alone or in the presence of 20 M forskolin. cAMP levels were 4.1 Ϯ 0.4, 4.2 Ϯ 0.5 and 4.3 Ϯ 0.4 pmol/ml (S.E., n ϭ 4) for 0, 5, and 10 M CoPo-22 alone, respectively, and 26 Ϯ 1, 22 Ϯ 2, and 23 Ϯ 2 pmol/ml for CoPo-22 plus forskolin. Addition of the phosphodiesterase inhibitor isobutyl methylxanthine (500 M) together with forskolin increased cAMP levels to 192 Ϯ 10, 214 Ϯ 18, and 207 Ϯ 26 pmol/ml.
Characterization of CoPo-22 Activity in Human A549 Cells. To test whether CoPo-22 is active in a different cell background, potentiator and corrector assays were done in ⌬Phe508-CFTR-transfected A549 cells, which are of human lung epithelial origin. Figure 6B (top) shows that CoPo-22 had potentiator activity in the A549 cells comparable with that in FRT cells. Apparent EC 50 for CoPo-22 potentiator activity was ϳ8 M (Fig. 6B) . However, CoPo-22 showed little corrector activity compared with Corr-4a when incubated for 24 h at 37°C (Fig. 6C, top) . We further tested CoPo-22 for corrector activity in A549 cells under the low-temperature synergy condition; however, we found that ⌬Phe508-CFTR was fully activated by forskolin (20 M) and genistein (50 M) in this cell model, precluding analysis of possible synergy (Fig. 6C, bottom) . Cellspecific corrector activity is well described ; however, the mechanism(s) responsible for cell typespecificity are not clear.
Discussion
We report here the identification of a novel class of cyanoquinolines, some of which have independent corrector and potentiator activities for normalization of defective ⌬Phe508-CFTR folding/ER retention and chloride channel gating, respectively. The dual corrector-potentiator activity of CoPo-22 is consistent with the possibility of binding to site(s) on the CFTR protein. The rapid normalization of defective ⌬Phe508-CFTR channel gating by CoPo-22 is probably a consequence of direct binding, as is its efficacy in the rapid activation of chloride conductance in wild-type and G551D-CFTR. The mechanism of CoPo-22 correction action is less clear.
The molecular mechanisms remain largely unknown by which ⌬Phe508-CFTR correctors partially promote ⌬Phe508-CFTR escape from the ER, allowing Golgi and plasma membrane targeting. The general possibilities include corrector action as a pharmacological chaperone by direct ⌬Phe508-CFTR binding to improve its folding efficiency and stability at the endoplasmic reticulum and plasma membrane and/or by influencing activity of the proteostasis network (Powers et al., 2009) . The latter may entail transcriptional, translational, and/or posttranslational modulations to enhance ⌬Phe508-CFTR biogenesis and/or to impede degradation. For example, ⌬Phe508-CFTR escape from the ER could be facilitated by extending its folding time and delaying degradation by inhibiting Rma1 and C terminus of Hsc70-interacting protein (CHIP), E3 ubiquitin ligases (Grove et al., 2009 ) and the 90-kDa heat shock protein cochaperone Aha1 (Wang et al., 2006a) . Initial studies of Corr-4a mechanism support the possibility of direct bithiazole-⌬Phe508-CFTR interaction (Pedemonte et al., 2005a) , because Corr-4a was ineffective in correcting other mutant membrane proteins for which pharmacological or low-temperature rescue is possible, including a non-⌬Phe508 CFTR mutant. Mutagenesis studies using a double-cysteine CFTR mutant, in which cross-linking occurs only when protein folds into native structure, suggested that Corr-4a interacts with ⌬Phe508-CFTR in the ER to promote its folding (Loo et al., 2008) , although this could be also an indirect consequence of Corr-4a effect via proteostasis. Although the peripheral stabilization of ⌬Phe508-CFTR in the presence of Corr-4a could be explained by a more native-like structure, recent evidence suggests that Corr-4a may interfere with the ubiquitination machinery (Jurkuvenaite et al., 2010) that is involved in disposal of rescued ⌬Phe508-CFTR from the cell surface (Okiyoneda et al., 2010) . Direct compelling evidence is lacking for the mechanisms by which correctors promote ⌬Phe508-CFTR plasma membrane targeting.
An interesting observation was the apparent dissociation of corrector and potentiator activities of the cyanoquinolines, in which some compounds have dual activities whereas others have only potentiator activity. SAR analysis indicated that replacing the flexible ethylene bridge, as found in CoPo-22 or CoPo-03, with a constrained six-or seven-membered ring diminished or abolished corrector activity. Several mechanisms could account for dissociation between corrector and potentiator activities. One possibility is distinct compound binding sites on ⌬Phe508-CFTR, or other secondary targets, for corrector and potentiator activities. Alternatively, the differential sensitivity of the protein quality control mech- anism and CFTR functional responsiveness may account for their discordant potentiator and corrector activities.
Although there are no prior published data on CoPo-22 or the cyanoquinoline analogs tested here, there are several reports in the patent literature on biological data for other compounds containing the cyanoquinoline core. Cyanoquinolines containing a six-or seven-membered ring with structure similar to CoPo-09 and CoPo-20 have been reported to inhibit neuronal degeneration and stimulate neurogenesis (Kelleher, 2007) . Cyanoquinolines have also been reported to have B-raf kinase inhibition activity for the potential treatment of cancer (Gahman et al., 2006) . Compounds containing only the cyanoquinoline core but with different bridging substituents have been described as orexin antagonists (Branch et al., 2002) and adenosine A2A receptor antagonists (Kosakata et al., 2005) . The patent literature thus suggests little cyanoquinoline toxicity. To our knowledge, ion channel-modulating effects of cyanoquinolines have not been reported.
Two classes of compounds had been described to have corrector and potentiator-like activities, the pyrazole 4-methyl-2-(5-phenyl-1H-pyrazol-3-yl)-phenol (VRT-532) (Wang et al., 2006a) and Corr-2b-related arylaminothiazoles (AAT) (Pedemonte et al., 2011) . VRT-532 was found to decrease ATP turnover rate by purified and reconstituted ⌬Phe508-CFTR and reduce ⌬Phe508-CFTR susceptibility to trypsin digestion (Wellhauser et al., 2009) . It was proposed that VRT-532 might bind directly to ⌬Phe508-CFTR and induce and/or stabilize a structure that promotes the channel open state. The mechanism of action of AATs is also unclear, although it was speculated that AATs bind directly to a different site from that of other potentiators, as evidenced by their similar efficacy for activation of G551D and other CFTR mutants.
In conclusion, the cyanoquinolines identified here have bona fide, dual ⌬Phe508-CFTR potentiator and corrector activities. Although their rapid, cell type-independent potentiator action on ⌬Phe508, G551D, and wild-type CF suggests direct CFTR binding, their corrector mechanism is less clear. The apparent dissociation of cyanoquinoline potentiator and corrector activities, which depended on chemical structure and cell type, suggests the possibility of a coincidental second site of action on ⌬Phe508-CFTR or other target(s) involved in cellular protein homeostasis. Further structural modifications of the cyanoquinoline scaffold are needed to improve compound potency and to identify analogs that are effective in human cell lines and primary bronchial cell cultures. Such compounds might be of use as a single-drug therapy of CF caused by the ⌬Phe508-CFTR mutation. Single-drug therapy has a priori advantages over multidrug therapy in terms of development costs and the probability of success. The alternative single-drug therapy for CF caused by the ⌬Phe508 mutation, which remains an unrealized possibility, is the identification of a highly effective corrector that normalizes ⌬Phe508-CFTR folding so as to obviate the need for potentiator activity.
